{"prompt": "['2017N323364 0', 'CONFIDENTIAL', '2019N398531_00', 'GlaxoSmithKline group of companies', '207626', 'TITLE PAGE', 'Protocol Title: A Phase IV, 12 week, randomised, double-blind, double-dummy study to', 'compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol', '(FF/UMEC/VI), with tiotropium monotherapy based on lung function and symptoms in', 'participants with chronic obstructive pulmonary disease', 'Protocol Number: 207626/01', 'Short Title: A randomised study, comparing FF/UMEC/VI single inhaler triple therapy', 'versus tiotropium monotherapy in participants with chronic obstructive pulmonary', 'disease', 'Compound Number: GSK573719+GW 642444+GW685698 (GSK2834425)', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information can be found in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s): IND number 114873, EudraCT Number', '2017-001190-16', 'Approval Date: 17-JUL-2018', 'Copyright 2018 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']['2017N323364_01', 'CONFIDENTIAL', '2019N398531_00', '207626', 'SPONSOR SIGNATORY:', 'PPD', '17 July 2018', 'Date', 'David A. Lipson M.D.', 'Project Physician Leader', 'PPD', '2']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 1', '17-Jul-2018', 'Original Protocol', '11-Oct-2017', 'Amendment 1 17-July-2018', 'Overall Rationale for the Amendment: This amendment is required to update the QTc', 'stopping criteria to that which was used in the Phase III Trelegy registration studies. In', 'addition, a section describing Smoking Cessation Counselling has been added as does a', 'corresponding assessment at the end of study (Visit 4). Clarified that run-in treatment', 'should be collected at Visit 2, study treatment at Visit 3, and albuterol/salbutamo at Visit', '5. Also, wording regarding suggested order for assessments and procedures has been', 'added to the end of the Schedule of Activities section. Removed reference to Fridericia', 'formula in calculation of QTc. Clarification regarding collecting the CAT assessment', 'questionnaire prior to the SGRQ-C has also been provided along with clarification that', 'vital signs should be collected before the ECG and prior to spirometry. Also added', 'clarification that CAT and SGRQ-C will both be collected at Visit 3 to mirror the SoA.', 'Corrected reporting time regarding pregnancy. Finally, added wording to Genetics', 'Appendix 9 regarding withdraw process and sample destruction process.', '3']\n\n###\n\n", "completion": "END"}